Medical Program: Emerging Roles for Immunotherapy in HER2+ Breast Cancer

Emerging Roles for Immunotherapy in HER2+ Breast Cancer

Emerging Roles for Immunotherapy in HER2+ Breast Cancer
RestartResume

What do we now know about the potential safety and tolerability of combining T-DM1 with pembrolizumab to treat patients with HER2+ breast cancer?

  • Overview

    What do we know now about the potential safety and tolerability of administering T-DM1 with pembrolizumab to patients with HER2+ breast cancer? Breast medical oncologist at the Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School Dr. Sara Tolaney explains these findings from her study that was presented at the 2020 ASCO Annual Meeting. 

Facebook Comments

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free